Printer Friendly

A. L. LABORATORIES STUDIES BUSINESS COMBINATION WITH APOTHEKERNES LABORATORIUM

 A. L. LABORATORIES STUDIES BUSINESS COMBINATION
 WITH APOTHEKERNES LABORATORIUM
 FORT LEE, N.J., April 10 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD), today announced that the company is studying the desirability and feasibility of combining some or all of the businesses of Apothekernes Laboratorium A.S. (A.L. Oslo) and A. L. Laboratories, Inc. in a stock transaction that would result in a single, publicly- traded company listed on the New York Stock Exchange.
 A.L. Oslo, a Norwegian pharmaceutical and animal health company, formed A. L. Laboratories, Inc. as a wholly owned subsidiary in 1975, and currently holds an approximate 48 percent ownership interest in A. L. Laboratories (38 percent assuming full conversion of outstanding convertible debentures). A. L. Oslo is a leading developer, manufacturer and marketer of pharmaceutical products in Scandinavia and, using internally-developed fermentation technology, has become the world's largest producer of the antibiotic, bacitracin, for pharmaceutical and animal health use. Utilizing its technological research capabilities, A. L. Oslo is an active 50 percent partner in a company that has developed and successfully commercialized, on a worldwide basis, advanced bioseparation techniques for diagnostic and medical applications.
 Given the complementary nature of their businesses, A. L. Laboratories, and A. L. Oslo have from time to time discussed and have decided to formally study the benefits of a combination because such a combined entity could be in a much stronger position to compete and grow as a worldwide specialized pharmaceutical and animal health company.
 A special committee of the board of directors of A. L. Laboratories, Inc. has been formed to evaluate the feasibility of this business combination. Neither the company nor A. L. Oslo has proposed any financial terms, and there is no assurance that a transaction will result from this study.
 A. L. Laboratories is a multinational manufacturer and marketer of specialized value-added branded pharmaceuticals and animal health micronutrients, with plant sites in Chicago Heights, Ill.; Niagara Falls and Glendale, N.Y.; Baltimore; Bellevue, Wash.; Copenhagen, Denmark; and Jakarta, Indonesia.
 -0- 4/10/92
 /CONTACT: Iris D. Daniels of A. L. Laboratories, 201-947-7774, or David Walke of Morgan-Walke Associates, 212-986-5900, for A. L. Laboratories/
 (BMD) CO: A. L. Laboratories, Inc.; Apothekernes Laboratorium A.S. ST: New Jersey IN: MTC SU:


SH-TS -- NY007 -- 7060 04/10/92 08:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 10, 1992
Words:382
Previous Article:BRAUN'S FASHIONS CORPORATION REPORTS FOURTH QUARTER AND FISCAL YEAR 1992 RESULTS
Next Article:MOBILE HABITAT FOR HUMANITY RECEIVES $50,000 WORTH OF BUILDING MATERIALS FOR HABITAT HOMES


Related Articles
A. L. LABORATORIES REPORTS FIRST QUARTER EARNINGS
A. L. LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS
A. L. LABORATORIES, INC. ANNOUNCES ACQUISITION
A. L. LABORATORIES REPORTS 1992 FULL-YEAR AND FOURTH QUARTER EARNINGS
A. L. LABORATORIES ANNOUNCES FIRST APPROVAL FOR ITS DENTURE STOMATITIS TREATMENT PRODUCT
A. L. LABORATORIES NAMES CYRILL SIEWERT AS ORAL HEALTH CARE PRESIDENT
A.L. LABORATORIES RECEIVES SHAREHOLDER APPROVAL OF PROXY MEASURES AND DECLARES REGULAR QUARTERLY DIVIDEND
A. L. LABORATORIES NAMES BETH POSNACK HECHT AS CORPORATE COUNSEL
New Directors in Statoil.
Reliability of IFCC method for lactate dehydrogenase in heparin plasma.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters